Atlas Trials

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT03208556 · UNKNOWN

Trial details

NCT number
NCT03208556
Sponsor
Peking University
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory B-cell Lymphoma
Start date
2017-06-21
Primary completion
2019-06-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.